GlassScriptPhysician profile
Crystal O Slade
NPI 1154332542
$3,323.37
in general payments reported to CMS, 2019-2025
29 companies · $501 in 2025
The $501 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $215 · 2021: $590 · 2022: $623 · 2023: $594 · 2024: $533 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,610 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,609.99 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $891.90 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $324.67 | 2020-2025 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $310.14 | 2023-2025 | Accrufer |
| Exeltis, USA INC. | $245.05 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $195.87 | 2021-2025 | |
| Pfizer INC. | $159.10 | 2023-2024 | |
| Viiv Healthcare Company | $122.46 | 2025 | Apretude |
| Sumitomo Pharma America, INC. | $115.04 | 2023-2024 | Myfembree |
| Coopersurgical, INC. | $99.12 | 2019-2024 | Paragard T 380a |
| Organon LLC | $76.97 | 2022-2025 | Nexplanon |
| Optumhealth Care Solutions, LLC | $74.36 | 2023-2024 | Vivify Health Care Team Portal, Zyno Solutions, Eitan Medical |
| Bayer Healthcare Pharmaceuticals INC. | $63.96 | 2019-2025 | |
| Scynexis, INC. | $60.68 | 2021-2022 | |
| Avion Pharmaceuticals | $59.14 | 2020-2021 | |
| Daiichi Sankyo INC. | $58.14 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $57.62 | 2025 | Zurzuvae |
| Agile Therapeutics, INC. | $54.37 | 2022 | |
| Millicent US INC | $53.05 | 2020-2025 | Intrarosa |
| Myovant Sciences INC. | $53.00 | 2022 | |
| Radius Health, INC. | $41.42 | 2021-2023 | Tymlos |
| Evofem Biosciences, INC. | $39.72 | 2022-2023 | Phexxi |
| Abbott Laboratories | $36.86 | 2025 | Eterna |
| Amgen INC. | $31.82 | 2019-2024 | Evenity, Prolia |
| Applied Medical Resources Corporation | $20.31 | 2023 | |
| Meditrina | $19.83 | 2022-2025 | |
| Smith+Nephew, INC. | $15.87 | 2025 | Pico 14 |
| Boston Scientific Corporation | $15.34 | 2022 | |
| Mylan Pharmaceuticals INC. | $13.88 | 2021 | |
| Minerva Surgical, INC | $13.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Slade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.